ADRA2A and type 2 diabetes mellitus: The third passage T2D ASCs were randomized into T2D ASCs, namely, the negative control (NC) group, Adra2a knockdown T2D ASC (knockdown) group, T2D ASCs treated with 10 μM clonidine (NC+C) group, and Adra2a knockdown T2D ASCs treated with 10 μM clonidine (knockdown+C) group.